Ketamine Tied to Rapid Relief of Depression Symptoms
A systematic review found that intravenous ketamine provides rapid relief for adults with major depressive disorder, significantly reducing suicidal thoughts and depressive symptoms within hours. The study analyzed 26 clinical trials with over 1,100 patients, highlighting ketamine's potential as an emergency treatment for high-risk patients. Despite its off-label use, ketamine is gaining attention for its fast-acting antidepressant effects, although it is not FDA-approved for psychiatric conditions.
- ▪Intravenous ketamine was associated with rapid relief for adults with major depressive disorder.
- ▪The study included 26 randomized clinical trials involving 1166 patients.
- ▪Ketamine showed significant reductions in suicidal symptoms within 24 hours after a single infusion.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/ketamine-tied-rapid-relief-depression-symptoms-suicidal-2026a1000fwv?src=rss |
| Publication time | Mon, 18 May 2026 03:56:47 EDT |
| Retrieval time | 2026-05-18T08:04:56.128Z |
| Last seen | 2026-05-18T08:04:56.128Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | _hCyq4hQpK44 |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Treatment with intravenous (IV) ketamine was associated with rapid relief for adults with major depressive disorder (MDD), providing significant reductions in suicidal thoughts and depressive symptoms within hours of a single infusion, a systematic review and meta-analysis found.The study, which analyzed 26 randomized clinical trials involving 1166 patients, updated evidence for ketamine as a fast-acting intervention in depression by incorporating more recent trials, including studies of repeated infusions.The speed of the antisuicidal effect could make IV ketamine a potential option in emergency treatment for patients at high risk for suicidal behavior, the researchers noted.“There is an urgent need for more effective interventions that rapidly reduce depressive symptoms and suicide…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
